Cellular therapies for rheumatic disease.

Area of Science:

• Immunology
• Rheumatology
• Cellular Therapy

Background:

• Cellular therapies, especially CAR T-cells, are emerging as viable treatments for autoimmune rheumatic diseases.
• Conventional therapies often fall short for conditions like systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc).

Purpose of the Study:

• To review the rationale, clinical experience, safety, and future directions of cellular therapies in rheumatology.
• To focus on the efficacy, safety, and immune reset potential of these therapies in autoimmune rheumatic diseases.

Main Methods:

• Review of current clinical data and studies on CAR T-cell therapy in rheumatic diseases.
• Analysis of safety profiles, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Main Results:

• CD19-directed CAR T-cells demonstrate significant B-cell depletion and high rates of drug-free remission in refractory SLE.
• Promising responses observed in SSc and IIM, with manageable toxicities (low-grade CRS, rare ICANS).
• Evidence of "immune reset" and the development of allogeneic and novel CAR platforms (CAR-NK, RNA CARs).

Conclusions:

• Cellular therapies offer transformative potential for severe, refractory autoimmune rheumatic diseases.
• Emphasizes the need for rigorous trial design, long-term safety monitoring, and equitable patient access.